The Assist CLAD Study - Mesenchymal Stromal Cell Therapy in Chronic Lung Allograft Dysfunction

Purpose: Mesenchymal stromal cells (MSC) are immunosuppressive and immunoregulatory. Following phase 1 confirmation of feasibility and safety, the ASSIST CLAD study was a multi-centre, phase 2, double-blind, randomised controlled clinical trial of intravenous (IV) allogenic bone-marrow derived MSC in lung transplant recipients with new onset chronic lung allograft dysfunction (CLAD).

Source: The Journal of Heart and Lung Transplantation - April 1, 2024 Category: Transplant Surgery Authors: , G. Westall, D. Darley, A. Glanville, M. Malouf, M. Musk, M. Sturm, C. Holmes-Liew, S. Lawrence, D. Bushell, L. Holsworth, N. Lawson, L. Singleton, S. Timmins, D. Enever, H. Wildermuth, O. Daka, B. Cooper, S.H. Apte, A. Pham, S. Haines, L. Zhang, M. Tan, Source Type: research